A detailed history of Private Capital Group, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Private Capital Group, LLC holds 21 shares of NTLA stock, worth $253. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Previous 80 73.75%
Holding current value
$253
Previous $6,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$38.49 - $76.21 $2,270 - $4,496
-59 Reduced 73.75%
21 $1,000
Q1 2022

Apr 21, 2022

SELL
$58.27 - $118.99 $58 - $118
-1 Reduced 1.23%
80 $6,000
Q4 2021

Jan 24, 2022

SELL
$100.76 - $138.36 $1,007 - $1,383
-10 Reduced 10.99%
81 $10,000
Q3 2021

Oct 13, 2021

BUY
$132.37 - $176.78 $9,265 - $12,374
70 Added 333.33%
91 $12,000
Q2 2021

Jul 26, 2021

BUY
$60.88 - $161.91 $1,278 - $3,400
21 New
21 $3,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.